News

Deal Announcements

Epiphany Biosciences Closes $36 Million Series A

Thursday, March 15, 2007 8:00:00 AM PDT | VentureDeal Staff
SAN FRANCISCO, CA -- Biotechnology company Epiphany Biosciences announced the closing of its first round of institutional financing, with $36 million in new investment.

The company is focused on discovering and developing "anti-infective agent" therapeutics.  It intends to use the financing proceeds to advance its shingle treatment drug candidate Valomaciclovir through phase 2b clinical trials.

Investors in the round were led by Wexford Capital, LLC, and included Windsor Bay Capital, LLC, Global Trust Ventures Management, CDIB BioScience Venture Management and several private investors.

Email Page  Email Page | Print Page Print Page

Free Trial

Want unlimited access to the complete database with thousands of technology companies, VCs and transactions for only $25 per month?

Start your Free 14 Day Trial now – no obligation or credit card required.

Free 14 day trial. No Obligation. Click to Register.
Venturedeal Twitter Venturedeal Facebook Venturedeal Linkedin


PCI - Level1